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ABSTRACT
Introduction Eczema care requires management of 
triggers and various treatments. We developed two online 
behavioural interventions to support eczema care called 
ECO (Eczema Care Online) for young people and ECO 
for families. This protocol describes two randomised 
controlled trials (RCTs) aimed to evaluate clinical and cost- 
effectiveness of the two interventions.
Methods and analysis Design: Two independent, 
pragmatic, unmasked, parallel group RCTs with 
internal pilots and nested health economic and 
process evaluation studies. Setting: Participants will 
be recruited from general practitioner practices in 
England. Participants: Young people aged 13–25 years 
with eczema and parents and carers of children aged 
0–12 years with eczema, excluding inactive or very 
mild eczema (five or less on Patient- Oriented Eczema 
Measure (POEM)). Interventions: Participants will be 
randomised to online intervention plus usual care or to 
usual eczema care alone. Outcome measures: Primary 
outcome is eczema severity over 24 weeks measured by 
POEM. Secondary outcomes include POEM 4- weekly for 
52 weeks, quality of life, eczema control, itch intensity 
(young people only), patient enablement, health service 
and treatment use. Process measures include treatment 
adherence, barriers to adherence and intervention 
usage. Our sample sizes of 303 participants per trial 
are powered to detect a group difference of 2.5 (SD 6.5) 
in monthly POEM scores over 24 weeks (significance 
0.05, power 0.9), allowing for 20% loss to follow- up. 
Cost- effectiveness analysis will be from a National 
Health Service and personal social service perspective. 
Qualitative and quantitative process evaluation will help 
understand the mechanisms of action and participant 
experiences and inform implementation.
Ethics and dissemination The study has been approved 
by South Central Oxford A Research Ethics Committee (19/
SC/0351). Recruitment is ongoing, and follow- up will be 
completed by mid-2022. Findings will be disseminated 
to participants, the public, dermatology and primary care 
journals, and policy makers.
Trial registration number ISRCTN79282252.
INTRODUCTION
Background and rationale
Eczema can cause substantial impact on 
quality of life, primarily because of sleep 
disturbance and itch.1 Families of children 
with eczema express frustration that they do 
not receive enough information about how 
to manage the condition,2 as do adults with 
eczema.3 The National Institute for Health 
and Care Excellence (NICE) guidance on 
eczema4 highlights that the main cause of 
treatment failure is non- adherence and there 
is a need for new ways to support adherence.5 
Strengths and limitations of this study
 ► Two large randomised controlled trials of online 
complex behavioural interventions addressing an 
important clinical need and research gap to support 
eczema self- care.
 ► Comprehensive intervention development following 
the person- based approach with extensive input 
from young people and families with eczema.
 ► Both trials include qualitative and quantitative pro-
cess evaluation to understand the interventions’ 
mechanisms of action and participant experiences.
 ► Cost- effectiveness of both interventions will be eval-
uated in nested health economic studies.
 ► Our primary outcome is self- reported eczema se-
verity using the Patient- Oriented Eczema Measure 
(POEM), but the lack of assessment of objective ec-
zema severity could be viewed as a limitation.
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Reasons for non- adherence include therapy being time- 
intensive,6 7 lack of understanding of treatments and 
how to use them,6 underuse of topical corticosteroids 
related to concerns about side effects,8 conflicting advice 
from different health professionals regarding how to use 
topical corticosteroids9 10 and child refusal.7
Self- care includes all the health behaviours needed to 
look after one’s own condition. Non- adherence is related 
to people’s understanding of their condition and its 
treatment, as well as perceived need for treatments and 
concerns about adverse consequences of treatments.11 
Self- care is particularly complex in eczema as it involves 
regular application of topical treatments (mainly emol-
lients for maintenance and topical corticosteroids for 
inflamed eczema) and avoidance of triggers (eg, soap). 
At present, many people and families receive little advice 
on how to manage the condition, or obtain advice of vari-
able quality from the internet.12 There is a need for high- 
quality, accessible interventions, as well as evidence of 
whether interventions work so that, if effective, clinicians 
can signpost towards these as an essential part of routine 
care.
Currently, 96% of British households have access to 
the internet, with 99% of adults being regular internet 
users.13 Although information about eczema is widely 
available on the internet, it is of variable quality, often 
promoting commercial products of unproven efficacy. 
Patients and parents/carers find it difficult to know which 
information is reliable.12
We have developed two web- based interventions to 
support eczema management: ECO (Eczema Care 
Online) for parents and carers of children aged 0–12 
years with eczema, and ECO for young people aged 13–25 
years with eczema. Parents of children with eczema and 
young people with eczema are likely to have different 
support and information needs. We have therefore devel-
oped two separate interventions to be evaluated in two 
separate randomised controlled trial (RCTs). This paper 
provides an abridged version of the full protocol that is 
available on the project website.14
Study objectives
The primary objective is to determine the clinical effec-
tiveness of two online interventions compared with usual 
care for eczema: one for young people aged 13–25 with 
eczema (ECO- YP) and one for parents and carers of chil-
dren aged 0–12 with eczema (ECO- PC).
The secondary objectives are (1) to determine the cost- 
effectiveness of the online interventions from a National 
Health Service (NHS) and personal social service perspec-
tive and (2) to determine the interventions’ mechanisms 
of action and factors related to participant engagement 
and treatment adherence and its outcomes.
Trial design
This protocol comprises two independent pragmatic, 
parallel group 1:1 allocation individually randomised 
superiority trials:
1. ECO- YP: to assess the effectiveness of an online in-
tervention in young people (YP) with eczema aged 
13–25 years as measured by Patient- Oriented Eczema 
Measure (POEM) 4- weekly scores over 24 weeks.
2. ECO- PC: to assess the effectiveness of an online inter-
vention in parents and carers (PC) of children with ec-
zema aged 0–12 years as measured by POEM 4- weekly 
scores over 24 weeks.
Total duration of follow- up will be 52 weeks with primary 
outcome assessed over the first 24 weeks.
METHODS AND ANALYSIS
Study setting
Primary care (general practitioner (GP) surgeries) in 
Wessex, West of England, East Midlands, and Thames 
Valley and South Midlands.
Recruitment
We will identify children with eczema aged 0–12 years and 
young people with eczema aged 13–25 years via an elec-
tronic records search developed by the study team and 
run by staff at the participating GP surgeries. A doctor or 
delegated member of the practice team will screen the 
identified list to assess suitability to receive a study invita-
tion. Potential participants will be sent an invitation pack 
containing the study URL and a unique code to register if 
they would like to take part. After registering on the inter-
vention website, the participants will be asked to provide 
informed consent and complete screening and baseline 
measures.
Parents or legal representatives of potential partici-
pants for ECO- YP aged 13–15 years will be sent informa-
tion about the study and a URL to provide online consent 
if they are happy for their child to take part. On receipt 
of parental consent, children aged 13–15 years old will be 
sent a participant invitation pack with the intervention 
website URL and unique ID to sign up if they would like 
to take part. Once registered, they will be asked to assent 
online.
Eligibility criteria
Eligibility for inclusion in ECO- YP: aged 13–25 years; 
identified from GP records as having eczema and have 
obtained a prescription for eczema treatment (emollient 
or topical corticosteroid) in the past 12 months; POEM 
score greater than 5, to include mild to severe eczema, 
but exclude those with very mild or inactive eczema to 
avoid floor effects; have internet access.
Eligibility for inclusion in ECO- PC: parent/carer of a 
child aged 0–12 years; child identified from GP records as 
having eczema and has obtained a relevant prescription 
in the past 12 months; child has a POEM score greater 
than 5, to include mild to severe eczema, but exclude 
those with very mild or inactive eczema; have internet 
access.
Only one person per household can take part in the 
trials. If a parent or carer has more than one child who 
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meets the inclusion criteria, they will be asked to specify 
one child to participate.
Potential participants from ECO- YP and ECO- PC are 
excluded if: unable to give informed consent; unable 
to read and write English, as the intervention content 
and outcome measures are in English; have taken part 
in another eczema study in the past 3 months; took part 
in think aloud interviews as part of ECO intervention 
development.15 Qualitative interviewees who did not view 
intervention materials will not be excluded. See figure 1 
for participant timeline.
Randomisation procedures and blinding
Participants will complete informed consent or assent and 
baseline questionnaires online within the intervention 
developed using LifeGuide software.16 Those who do not 
meet the eligibility criteria of a minimum POEM score 
greater than 5 are presented with information explaining 
that they are not eligible for the study and signposted to 
other resources.
Eligible participants are randomised online to either 
(1) usual eczema care or (2) online intervention plus 
usual care through LifeGuide software. Randomisation is 
carried out in blocks and stratified by age (13–17; 18–25 
(ECO- YP), and 0–5; 6–12 (ECO- PC)), baseline eczema 
severity (POEM scores 6–7 (mild); 8–16 (moderate); 
17–28 (severe)) and recruitment region as these may 
influence how participants engage with the interventions.
It is not possible to mask participants to their allocation 
group. Participants are informed online as to which group 
they have been allocated to immediately after randomisa-
tion and are notified by email. The immediate trial team 
dealing with participant queries will have access to group 
allocation, but the wider Trial Management Group and 
trial statistician will remain blinded.
Intervention and group details
Usual care group
Participants randomised to usual care will continue to 
receive their usual medical advice and prescriptions. 
They can seek online support but will not be supported 
in doing so by the study team and will not have access to 
the online interventions during their participation in the 
trial. Participants allocated to the usual care group will be 
given access to the intervention after 52- week follow- up is 
complete.
Behavioural intervention groups (ECO-YP and ECO-PC)
Participants randomised to the intervention group will 
receive access to an online behavioural intervention to 
support eczema self- care in addition to usual eczema care, 
as above. The interventions were developed following the 
person- based approach to intervention development17 18 
to ensure they are meaningful, optimally engaging and 
relevant to target users, and draws on a theoretical frame-
work including the Extended- Common Sense Model,19 
Social Cognitive Theory,20 the Behaviour Change Wheel 
and associated Theoretical Domains Framework.21 All 
intervention content is evidence- based, and the interven-
tions are tailored and include interactive and audio- visual 
features. The interventions were initially developed by 
the research team consisting of behavioural psychologists, 
patient representatives, clinicians (GPs, dermatology 
nurse consultant, dermatologists) and skin researchers 
before being optimised through extensive user feedback 
to ensure they are acceptable, feasible and optimally 
engaging to target users.22
The online interventions target core behaviours linked 
to eczema management:
 ► Regular use of emollients and appropriate use of 
topical corticosteroids.
 ► Avoiding eczema irritants and triggers.
 ► Minimising scratching.
 ► Emotional management.
The interventions use behavioural techniques to 
promote adherence and support eczema self- care by 
building on aspects like knowledge, skills, self- efficacy, 
social support and environmental factors such as social 
and physical opportunity.
The interventions take participants through a core 
section before giving access to the main menu with the 
choice of various topics of interest to young people and 
families with eczema. These topics include eczema treat-
ments, infections, talking to your healthcare professional, 
Figure 1 Flow of participants through the trial. GP, general 
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diet and allergy, sleep and itch, physical activity, coping 
with stress and transitioning to self- care. The interven-
tions also include a ‘2- week challenge’ where participants 
are encouraged to use their eczema treatment regu-
larly for 2 weeks, supported by optional text and email 
reminders and support. Intervention content has been 
developed to be interactive and engaging, with tailoring 
to suggest topics that may be of relevance. The interven-
tion also contains a series of animated videos focussing on 
the core target behaviours.
ECO- YP has been developed for people aged 13–25 
years with eczema. The intervention covers the topics 
mentioned above, as well as additional topics that are 
important particularly to this age group, such as infor-
mation about finances, school, university, or work and 
cosmetics.
ECO- PC has been developed for parents of children 
aged 0–12 years with eczema. This intervention covers 
the same wide range of topics relevant to eczema, as 
well as sections that are specifically relevant to parents 
and co- management of eczema, such as transitioning 
to co- management, dealing with child resistance and 
managing your child’s eczema at nursery and school. 
Intervention description follows TIDieR guidelines23; 
detailed intervention development and optimisation 
studies will be published separately.
Outcomes
All participant- reported outcome measures and inter-
vention usage data are collected online via LifeGuide 
software. Outcome measures are similar across ECO- YP 
and ECO- PC, where there are differences, these are 
highlighted (table 1). POEM, RECAP and itch intensity 
measures have been recommended as core outcome 
measures for eczema by the international Harmonising 
Outcome Measures for Eczema group.24 25
Primary outcome
The primary outcome for both trials is the difference in 
patient- reported eczema severity between the interven-
tion and usual care group as measured by POEM, every 4 
weeks over 24 weeks.26 27
POEM includes seven questions about the frequency 
of eczema symptoms over the previous week that are 
summed to give a score from 0 (no eczema) to 28 (worst 
possible eczema). POEM can be completed by young 
people and children or by proxy (carer report, ECO- 
PC), demonstrates good validity, test–retest reliability and 
responsiveness to change.28
Secondary outcomes
Secondary outcomes include (1) difference in POEM 
scores 4- weekly over 52 weeks; (2) quality of life at 24 and 
52 weeks, measured in ECO- YP, using the EQ- 5D- 5L29 self- 
completed by the young person, and in ECO- PC by proxy 
using the Child Health Utility- Nine Dimensions (CHU- 
9D)30 for children aged 2–12 years; (3) eczema control at 
24 and 52 weeks, measured by RECAP (Recap for atopic 
eczema patients)31; (4) itch intensity32 at 24 and 52 weeks, 
measured as worst itch in the last 24 hours (not validated 
for proxy completion for children, and therefore used in 
ECO- YP only); (5) patient enablement at 24 and 52 weeks, 
the self- perceived ability to understand and cope with 
health issues, will be measured using the Patient Enable-
ment Instrument (PEI)33; (6) health service use and 
medication use, measured by medical notes review for the 
3- month period prior to baseline and the whole 52- week 
trial period; (7) cost- effectiveness combining quality of 
life and health service use and medication use.
Other measures
Prior belief about the effectiveness of the intervention 
and online resource use (websites or apps) for eczema 
will be measured at baseline and will be used in a 
planned subgroup analysis to explore whether there is an 










Prior belief about 
effectiveness
✓




POEM (4- weekly) ✓ ✓ ✓
Long- term control 
(Recap)
✓ ✓ ✓







CHU- 9D (ECO- PC for 
parents/carers of children 
aged 2–12 only)
✓ ✓ ✓
EQ- 5D- 5L (ECO- YP only) ✓ ✓ ✓
Medical notes review for 
medication use, service 
use and referrals




of Therapy Scale (PETS)
✓ ✓ ✓




Intervention usage ✓ (recorded 
throughout study)
POEM, Patient- Oriented Eczema Measure.
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interaction between prior belief, online resource use and 
treatment effectiveness.
Process measures
Self- reported barriers to adherence to eczema treatments 
will be measured at 24 and 52 weeks using the Problematic 
Experiences of Therapy Scale (PETS)34 and frequency 
of eczema treatment use (treatment adherence) will be 
measured by self- report. Intervention usage data for each 
participant will be automatically recorded by LifeGuide 
software for the duration of the 52- week trial period.
Internal pilot phase
The first 3 months of participant recruitment was an 
internal pilot phase to test trial procedures, which 
mirrored the main trial protocol exactly. We assessed 
study uptake, recruitment and follow- up procedures, 
randomisation and participant engagement in accessing 
the intervention. Success criteria for the pilot phase are 
listed in the full protocol (available from ECO website).14
Data collection methods and retention
All study procedures are automated and carried out online 
through the LifeGuide software.16 Participants wishing to 
take part in the study provide consent and assent (where 
required) and complete an online baseline questionnaire 
before being randomised to either the usual care group 
or the intervention group. Participants in the interven-
tion group then have access to the intervention website 
(either ECO- YP or ECO- PC).
All participants are asked to complete a 4- weekly 
POEM questionnaire online for 52 weeks. Participants 
are also asked to complete a longer 24- week and 52- week 
follow- up questionnaire online. When signing up for the 
trial participants are asked if they would prefer reminders 
by email, text message or both. Automated emails and/
or text messages are sent to notify participants when their 
follow- up questionnaires are available for completion. 
Reminders will be sent to non- responders after 5 days 
(and after 10 days for 24- week and 52- week question-
naires), followed by reminder telephone calls approxi-
mately 4 days later from the research team, at which point 
participants will be invited to complete selected follow- up 
questions over the phone.
Sample size
The sample size calculation for ECO- YP and ECO- PC is 
based on 4- weekly POEM scores using repeated measures 
over the first 24 weeks of the trial, seeking to detect a 
minimum clinically important difference (MCID) of 2.5 
points between groups (SD 6.5). Assuming a correlation 
between repeated measures of 0.70, with 90% power and 
5% significance, this requires a total sample size of 121 
per group in each of the two trials. Allowing for 20% loss 
to follow- up gives a total sample size of 303 in each of the 
two trials. The sample size was amended during the trial, 
see the Protocol amendments section for details.
Statistical analysis plan
Primary analyses of the ECO- YP and ECO- PC trials will 
be generalised linear mixed models, allowing for obser-
vations nested within participants over time. All analyses 
will control for key covariates, including age and baseline 
eczema severity, and will be set out in full in the statis-
tical analysis plan prior to database lock. For secondary 
outcome measures, linear models will be used for contin-
uous outcomes. Where the assumptions for linear models 
are not met, we will use other appropriate distributions 
or non- parametric methods if no suitable distribution 
can be found. Logistic regression will be used for binary 
outcome measures.
We will collect data on use of other websites at the start 
and end of the trials to check whether there is a differ-
ence between groups in accessing other eczema sites and 
plan sensitivity analyses to examine whether accessing 
other resources affects outcomes. All trials of online 
interventions must assume that users in both groups may 
access other websites, and so trials provide a useful test of 
whether the intervention being evaluated is superior to 
the websites users can already access.
All analyses will be on an intention- to- treat basis (anal-
ysed as randomised), detailed in the statistical analysis 
plan, and include participants from the internal pilots and 
full RCTs. No interim analyses are planned. The structure 
and pattern of missing data will be examined, if appro-
priate, and a sensitivity analysis based on data imputed 
using a multiple imputation model presented. Findings 
will be reported in accordance with the CONSORT 
(Consolidated Standards of Reporting Trials) statement.
Health economic evaluation
Two within trial economic evaluations will estimate 
whether ECO- YP and ECO- PC are cost- effective compared 
with usual care from an NHS and personal social services 
perspective. We will estimate the cost of the interven-
tions and collect data on wider resource use (primary 
care, secondary care and accident and emergency use) 
and eczema- related prescriptions through medical notes 
review. Resource items will be valued using published unit 
costs for the most recent common price year to the time 
of analysis.
There is currently no agreed approach to valuing health 
outcomes in children in economic evaluations and there 
has been limited use of child and adolescent population- 
specific measures to generate health state utilities in NICE 
technology assessments.35 In ECO- PC for parents and 
carers of children aged 0–12, we will collect by proxy the 
CHU- 9D,36 a paediatric generic preference- based instru-
ment, in those aged 2 and older. Although the CHU- 9D 
was developed for children aged 7 and older, its comple-
tion by proxy in younger age groups is currently being 
trialled36 and the developer of the instrument has given 
us additional guidance to use with parents and carers with 
children in this age group. This approach is being taken 
















pen: first published as 10.1136/bm





6 Muller I, et al. BMJ Open 2021;11:e045583. doi:10.1136/bmjopen-2020-045583
Open access 
In the ECO- YP (young people aged 13–25), all partic-
ipants are asked to self- complete the EQ- 5D- 5L in order 
to estimate their health- related quality of life. To prevent 
any discontinuity, the EQ- 5D- Y will not be used in those 
under the age of 16 as this is a different instrument 
from the EQ- 5D- 5L.37 38 All participants will be asked to 
complete the EQ- 5D- 5L at baseline, 24 and 52 weeks and 
the scores from these will be converted to utility scores 
using UK preference weights in line with current recom-
mendations at the time of the analysis.37 39 Following this, 
the utility values will be used to estimate quality- adjusted 
life years (QALY) for the trial period using linear interpo-
lation and area under the curve with and without baseline 
adjustment.40
Cost- effectiveness (using change in POEM between 
baseline and 52 weeks, secondary analysis) and cost utility 
analyses (primary analysis) will be performed. Costs and 
benefits will not be discounted given the 12- month time-
frame. Using information on costs and benefits, regres-
sion analysis will be conducted to estimate the incremental 
cost, incremental benefit and incremental cost utility of 
the online intervention compared with usual care (over 
the trial period). If one arm is clearly dominant (less 
costly and more effective), a recommendation can be 
made on this basis. If non- dominance occurs (that is if 
costs are greater and the intervention is more effective 
or if the intervention is cheaper and less effective), an 
incremental cost- effectiveness ratio will be produced and 
a judgement about value for money will need to be made. 
The economic evaluation will be undertaken and anal-
ysed in line with guidelines.41 42 Missing data will be dealt 
with in line with the approach taken in the main clinical 
statistical analysis, with sensitivity analysis undertaken to 
test the impact of approach if missing data is a particular 
problem. A detailed health economic analysis plan will be 
written and reviewed before the trial database is locked.
Nested process evaluation
The nested process evaluation studies are being carried 
out to understand intervention processes and partici-
pants’ experiences of using the interventions.
Quantitative process evaluation
We will use baseline data to examine potential predic-
tors and moderator effects of participant characteristics 
(eg, age, eczema symptom severity, baseline attitudes) on 
intervention engagement (objectively recorded detailed 
website usage and self- reported treatment adherence) 
and outcome. We will also assess and analyse hypothe-
sised mediators of treatment adherence and intervention 
outcomes; specifically changes in beliefs about treatment 
(PETS) as well as intervention usage. Objective measures 
of intervention usage are automatically recorded (with 
informed participant consent), allowing evaluations 
of usage patterns, such as time spent on intervention, 
number of visits to the intervention website and pages 
visited.
Qualitative process evaluation
Qualitative process interviews will be carried out with 
approximately 30–40 participants (15–20 from ECO- YP 
and 15–20 from ECO- PC, or until saturation of the main 
themes are achieved). These interviews will provide 
in- depth understanding of patient and carers’ experi-
ences within the trial and provide a better understanding 
of factors that may influence engagement.
Interviews will be conducted via telephone or video call 
by a member of the research team experienced in qualita-
tive research methods. We will interview participants from 
the intervention group and the usual care group and use 
purposive sampling to ensure a range of age, gender, 
ethnicity, eczema severity, website usage, deprivation 
index and region. Potential participants will be contacted 
after being in the trial for at least 3 months by a member 
of the research team to check whether they would like 
to take part in an interview or have any questions about 
the study. Participants will be asked to give their consent 
online prior to the interview. Interviews will use a combi-
nation of open- ended and focused questions and be tran-
scribed verbatim.
Qualitative data will first be analysed using inductive 
thematic analysis.43 We will then explore how emerging 
themes may map onto theoretical frameworks in order to 
relate our insights to generalisable theoretical constructs 
and inform implementation planning.
Process evaluation analysis
We will triangulate findings from the quantitative and 
qualitative process analyses44 to explore and test the 
causal mechanisms proposed, to help inform interpreta-
tion of trial results, and determine how the interventions 
could be improved and how implementation into clinical 
practice could be facilitated.
Patient and public involvement
The study team includes two patient and public involve-
ment (PPI) members (AR and AA) who have been 
involved in the project from the earliest stages. They 
are involved in all aspect of the ECO programme and 
trials, including intervention development,22 trial design, 
attending trial and programme management meetings, 
protocol discussions, developing participant facing mate-
rials and coauthoring outputs. Our PPI partners will also 
be key for dissemination and future implementation.
ETHICS AND DISSEMINATION
The study has received the favourable opinion of South 
Central–Oxford A Research Ethics Committee (19/
SC/0351). This summary protocol is based on approved 
protocol v3 (20/05/2020), ISRCTN reference 79 282 252.
Data monitoring
An independent Programme Steering Committee take 
responsibility for safeguarding the interest of study partic-
ipants, monitor the main outcome measures including 
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safety and efficacy, and monitor the overall conduct of 
the trials.
Protocol amendments
One substantial protocol amendment has been made 
since initial ethics approval (Substantial Amendment 1, 
number 47369.A4, approved 01/06/20). This amend-
ment was in response to the COVID-19 pandemic in 
order to:
1. Make all trial process online. The original protocol re-
quired parents or guardians of 13–15 year olds to re-
turn parental consent by post.
2. Increase in sample size. Our original sample size was 
200 participants per trial, based on the published 
POEM MCID of 3.45 However, research has since sug-
gested that a smaller POEM MCID may be meaning-
ful in certain contexts.46 Recruitment to both trials 
exceeded expectation and a protocol amendment was 
made to change the sample size to a minimum of ‘200 
participants’ per trial to allow us to continue recruit-
ment while a revised sample size was discussed with our 
Trial Management Group, Programme Management 
Group, Programme Steering Committee and funder, 
without access to study outcome data or any interim 
analysis. The final agreed sample size for the trials were 
based on seeking to detect a POEM MCID of 2.5 points 
between groups, based on two repeated measures (SD 
6.5), allowing for 20% loss to follow- up requiring sam-
ple size of 303 participants in each of the two trials.
Dissemination
As a minimum, study progress, outputs and trial findings 
will be made available via the study website14 and project 
twitter (@ECO_eczema). Summaries will also be sent 
to participants and participating GP surgeries. Findings 
will be presented at conferences and published in peer- 
reviewed journals. We will make available a deidentified 
dataset on request.
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